Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $58.0 million.

  • Anika Therapeutics' Cash & Equivalents fell 701.96% to $58.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.0 million, marking a year-over-year decrease of 701.96%. This contributed to the annual value of $55.6 million for FY2024, which is 1907.33% down from last year.
  • Latest data reveals that Anika Therapeutics reported Cash & Equivalents of $58.0 million as of Q3 2025, which was down 701.96% from $53.2 million recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Cash & Equivalents ranged from a high of $97.2 million in Q2 2021 and a low of $53.2 million during Q2 2025
  • In the last 5 years, Anika Therapeutics' Cash & Equivalents had a median value of $70.7 million in 2023 and averaged $75.3 million.
  • Per our database at Business Quant, Anika Therapeutics' Cash & Equivalents skyrocketed by 4369.54% in 2021 and then plummeted by 2880.01% in 2023.
  • Anika Therapeutics' Cash & Equivalents (Quarter) stood at $94.4 million in 2021, then fell by 8.54% to $86.3 million in 2022, then fell by 20.37% to $68.7 million in 2023, then fell by 19.07% to $55.6 million in 2024, then increased by 4.24% to $58.0 million in 2025.
  • Its Cash & Equivalents was $58.0 million in Q3 2025, compared to $53.2 million in Q2 2025 and $53.4 million in Q1 2025.